	OIPE J	GA)	1:1646
011	MAY 2 2 2000 E		BOXSEQ
MAY 2	IN THE NITED STATES PATI	ENT AND TRADEMARK OFFICE	0/120
TRAL	n re Patent Application of	) Group Art Unit: 1646 )	July or
	Ameae M. Walker	Examiner: Christine Saoud, Ph	=CEIVED WI''
	Serial No.: 09/065,330		
	Filed: April 23, 1998	) )	ECH CENTER 1600/2900
•	For: PROLACTIN ANTAGONISTS AND USES THEREOF	) San Francisco, Californi	ia
•	Assistant Commissioner for Patents Washington, D.C. 20231		7
		oosited with the United States Postal Service as first class mail or for Patents, Washington, D.C. 20231 on May 18, 2000.	三 23 河
	Julie M. Balot  SEOUENCE LIST	TING TRANSMITTAL	M00M
	Sir:  Transmitted herewith are the follow		the Examiner's

Communication dated April 18, 2000:

- Four pages of a revised substitute Sequence Listing;
- A disk containing the Sequence Listing (formatted in MS DOS Text); 2.
- A Statement of J. Suzanne Siebert; and 3.
- A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. 4.

Dated: May 18, 2000.

Respectfully submitted,

J. Suzanne Siebert, Reg. No. 28,758

MAJESTIC, PARSONS, SIEBERT & HSUE P.C.

Four Embarcadero Center, Suite 1100 San Francisco, California 94111-4106

Telephone: (415) 248-5500 Facsimile: (415) 362-5418

Atty. Docket: 2500.097US2



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	) Group Art Unit: 1646
In re Patent Application of	) Group Aut Chief
Ameae M. Walker	) Examiner:
Serial No.: 09/065,330	) Christine Saoud, Ph.D.
Filed: April 23, 1998	)
For: PROLACTIN ANTAGONISTS AND USES THEREOF	) ) San Francisco, California
Assistant Commissioner for Patents	

Washington, D.C. 20231

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 18, 2000.

STATEMENT OF J. SUZANNE SIEBERT

Sir:

The undersigned, J. Suzanne Siebert, declares:

The attached paper copy and the computer readable form of the submitted "Sequence

Listing" are of the same content and the submission includes no new matter.

Dated: May 18, 2000.

Attorney for Applicants

Atty. Docket: 2500.097US2

RECEIVED

WAY 25 2000

FECH CENTER 1600/2000

OIPE	App Cation No. 09/165,330
MAYNOFICE TO COMPLY WITH I	REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING DISCLOSURES
The nucleotide and/or amino the nucleotide and/or amino the following real three following real transfer is the following real transfer in the following real transfer in the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following real transfer in the following real transfer is the following re	o acid sequence disclosure contained in this application does ements for such a disclosure as set forth in 37 CFR 1.821 - ason(s):
1. This application - 1.825. Applicant's atte May 15, 1990 and at 55 FR	n clearly fails to comply with the requirements of 37 CFR 1.821 ention is directed to these regulations, published at 1114 OG 29, 18230, May 1, 1990.
· []	n does not contain, as a separate part of the disclosure on
paper copy, a "Sequence Li	isting" as required by 37 CFR 1.821(c).  Sequence Listing" in computer readable form has not been
submitted as required by	37 CFR 1.821(e).
However, the content of tof 37 CFR 1.822 and/or 1. Sequence Listing."	"Sequence Listing" in computer readable form has been submitted. the computer readable form does not comply with the requirements are selected as indicated on the attached copy of the marked-up "Raw". 823, as indicated on the attached copy of the marked-up "Raw".
found to be damaged and/or Report. A substitute con 1.825(d).	eadable form that has been filed with this application has been or unreadable as indicated on the attached CRF Diskette Problem mputer readable form must be submitted as required by 37 CFR
6. The paper copy readable form of the "Se	of the "Sequence Listing" is not the same as the computer equence Listing" as required by 37 CFR 1.821(e).
7.	
Other:	ide:
<del>-</del> ·	stitute computer readable form (CRF) copy of the "Sequence
V	ostitute paper copy of the "Sequence Listing", as well as an
	the ontry into the specification.
A statement that and, where appli	the content of the paper and computer readable office of the paper and computer readable of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the paper and computer readable of the content of the
For questions regar	ding compliance with these requirements, please contract
,	$c_{2} = c_{2} = c_{2$
For CRF submission For PatentIn softwa	help, call (703) 308-4212 are help, call (703) 557-0400

Please return a copy of this notice with your response.